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James Alexander Logan, a second-year medical student at the 
Barts and The London School of Medicine and Dentistry, died 
in February 2001 after a distressing illness of three months 
duration. His family, friends and interested professionals 
subsequently set up the James Logan Trust1 to encourage 
doctors and others to have the confidence to recognise and 
treat cancer pain. The trustees were not oblivious of the need 
for the proper recognition and treatment of pain arising in 
other conditions but they wished specifically to improve 
the general management of cancer pain and they felt that 
confidence and skill acquired in this could be applied in 
other cases.
Until pain is recognised it cannot be assessed or treated, and 
the recognition of pain, like the recognition of so many other 
conditions, depends almost entirely on listening to the patient 
and accepting what is being said. Once it is acknowledged 
that pain is present then treatment should follow. The Trust 
recognises that specialist palliative care teams provide an 
essential service especially when pain is severe and un-
relieved by standard mediation but their existence does not 
absolve other doctors, no matter how junior or senior, from 
doing their best to treat pain promptly and effectively. The 
Trust would encourage every doctor to have the confidence 
to start a patient on simple pain-relieving medication and 
to know how and when to increase it according to well 
established guidelines.2
The James Logan Trust has provided funds for an annual 
prize for the best essay on “The challenges of cancer pain 
assessment and management” to be submitted by a Queen’s 
University of Belfast undergraduate medical student after the 
completion of their fourth-year palliative medicine teaching. 
The University and its Palliative Medicine Undergraduate 
Curriculum Committee were instrumental in setting up the 
James Logan Essay Prize and the essays are to be judged 
by at least two members of the latter committee. The Trust 
is indebted to the University and to the Committee for their 
assistance.
The first essays were submitted in the summer of 2010 and the 
winning entry, written by Mrs Victoria Campbell, is published 
in this issue. The Trust congratulates Mrs Campbell on her 
effort and wishes her and the other essayists well in the future.
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Both acute and chronic pain has been well documented as one 
of the most frequent and distressing symptoms in cancer, and 
has been shown to adversely affect quality of life.1-5 While 
it is difficult to be precise, it has been estimated that pain is 
present in 36-61% of patients depending on cancer type, stage 
of disease, and patient setting e.g. in-patient or out-patient.1 Of 
those patients with advanced cancer, at least 64% have been 
shown to experience pain.6 The magnitude of the problem 
has been acknowledged by the World Health Organization 
who first published the analgesic ladder in 1986 in an attempt 
to establish guidelines for cancer pain management.7  Yet 
despite advances in policy, diagnosis and treatment since then, 
research suggests that cancer pain relief is still inadequate.3,8-9  
This contradicts alternative research which has proposed that 
effective treatment of pain should be feasible for 70-90% of 
oncology patients.8,10 The purpose of this essay will be to 
review those factors that may be contributing to the cancer 
pain problem, and also to consider any solutions which have 
been proposed in the literature. 
It is widely accepted that assessment is the first step in the 
management of pain, indeed a comprehensive understanding 
of pharmacological and non-pharmacological pain 
management is of little value if the assessment of pain is 
inaccurate.11-12 The current standard approach to the initial 
assessment of cancer pain includes a detailed history 
and physical examination, assessment of psychosocial 
circumstances, and a diagnostic work-up.  It is important 
to consider what may be causing the pain, as well as to ask 
about pain intensity.11 The specific challenge of cancer pain © The Ulster Medical Society, 2011.
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assessment lies in its subjective and evolving nature.  Cancer 
pain is multifaceted, and clinically may be described as acute, 
chronic, nociceptive (somatic), visceral, or neuropathic.5   
Indeed a combination of all these subtypes may be present 
in any given patient at any one time.  Furthermore, pain 
characteristics evolve over time due to changes in underlying 
pathophysiology.12 Together these factors make the challenges 
to cancer pain assessment obvious, and it has been suggested 
that no individual assessment tool exists that adequately 
and accurately captures the multidimensional phenomenon 
of cancer pain.5,12  This was well demonstrated by de Wit 
and colleagues who showed, using different assessment 
methods in the same patient population, that the percentage 
of uncontrolled cancer pain ranged from 16-96% depending 
on the method used to quantify it.13   The absence of a 
standardised approach to cancer pain assessment not only 
means that pain is  being inadequately treated, but also 
exposes the limitations of comparing research results in 
cancer pain management.11     
In the literature, one of the main pitfalls of cancer pain 
assessment is failure to properly listen to the patient’s 
complaint of pain, and to establish an accurate measure of 
pain intensity.11,14-16  The development of a pain classification 
system is complicated by the factors mentioned above, 
however in the same way that the TNM Classification System 
has been a common language between oncology specialists for 
some decades, it has been recommended that a useful approach 
to cancer pain assessment is to use either a standardised visual 
analogue scale or a numerical scale.11-12  The problem with 
these scales is that they are a one-dimensional assessment of 
pain intensity.  In an attempt to develop a multidimensional 
assessment of pain Bruera and colleagues17 developed the 
Edmonton Staging System (ESS) to assess and classify pain 
on the basis of seven characteristics, including mechanisms 
of pain, presence of incidental pain, daily opiate use, 
cognitive function, psychological distress, tolerance, and 
past history of alcohol or drug addiction.  Patients were 
defined as having a good, intermittent, or poor prognosis 
for pain control based on a combination of these features.11 
Like other cancer pain classification tools, clinical use of the 
ESS was limited by problems with definitions of some of the 
constructs.  An evaluation of the ESS in 276 patients found it 
to be highly sensitive but with poor specificity.18 In response 
to its limitations, the ESS was later evaluated by a panel of 
experts and renamed as the Edmonton Classification System 
for Cancer Pain (ECS-CP).19  Despite this, some researchers 
maintain that there is still no internationally accepted tool for 
cancer pain assessment.11 
The literature suggests that inadequate pain management is 
a function of a number of factors, including misconceptions 
about the use of drugs commonly used to treat cancer pain, 
and a lack of communication between patients and clinicians, 
in addition to the absence of formal assessment procedures 
as outlined above.3 With regards pain management following 
initial assessment, numerous barriers have been documented 
that prevent patients from receiving effective pain treatment, 
and challenge clinicians when providing adequate pain relief.   
These barriers have been divided into patient-related as well 
as professional-related barriers, and together they contribute 
significantly to the challenges of cancer pain management.1,3-5  
Several studies have reported professional-related barriers that 
hinder cancer pain management.  A recent systematic review 
of these studies found that nurses and doctors reported the 
following barriers most frequently: a) inadequate assessment 
of pain and pain management, b) patients’ reluctance to 
report pain or to give a pain score, and c) professionals’ 
inadequate knowledge of pain management.1   Specifically, 
misconceptions expressed by health professionals have 
centred around the use of morphine in the treatment of cancer 
pain.  A study by Elliott and Elliott surveyed 243 physicians 
and found approximately half to have misconceptions 
about drug tolerance, believing that an increased need 
for morphine was indicative of tolerance as opposed to 
increasing pain intensity.  Over 20% had misconceptions 
about opiate addiction, though fewer oncologists expressed 
this misconception.  Other misconceptions centred around 
opiate side effects and administration, with many physicians 
indicating that parenteral administration is the only route 
available when treating severe cancer pain.  Perhaps the most 
concerning finding was that almost 20% of physicians believed 
that pain associated with cancer is inevitable and cannot be 
fully alleviated through treatment.3,20 Other studies since then 
have yielded comparable findings.3  The overestimation of 
addiction and an over-inflated fear of respiratory depression 
and other opiate side effects, has regrettably led to widespread 
under-treatment of pain in cancer patients.5,21  Physicians 
themselves have acknowledged education in the area of cancer 
pain management to be inadequate.22
Like some health-professionals, patients and their families can 
add to the challenge of cancer pain management due to their 
misconceptions about analgesics and their side effects.1,3-5  
This in turn can lead to non-adherence to treatment regimens 
and poor communication of concerns about pain to medical 
staff.3  Patients may not report pain for a variety of reasons, 
ranging from a desire not to ‘bother’ the doctor, to concerns 
that they are not being a ‘good’ patient, or a fear that their 
pain is indicative of disease progression and avoidance of 
this possibility.  They may be reluctant to take their pain 
medication due to fears of becoming addicted or tolerant.   
They may also have concerns about side effects, or fear that 
the medications are ‘bad’ for their bodies.3 In 1993 Ward 
and colleagues23 surveyed 270 cancer patients to assess their 
concerns regarding the use of analgesics and the reporting of 
their pain to medical staff.  The patients were given a 27-item 
questionnaire called the Barriers Questionnaire (BQ) and 
also the Brief Pain Inventory (BPI) to measure pain intensity.   
Ward found that many of the patients surveyed expressed 
some concern over issues relating to pain management, 
with concerns about addiction receiving the highest mean 
score.  Patients who were older, had lower incomes, and less 
education had more concerns about pain management.3,23  
Further patient-related barriers were highlighted by a recent 
systematic review which analysed fourteen studies looking 
at adherence to analgesics by cancer patients.1  One of these 
studies, by Lai and colleagues24, showed that the stronger 
patients believed they could control their pain themselves, 
the less likely they were to adhere to treatment.  In addition, 
the stronger they believed that medication was necessary for 
their pain, the more they adhered to treatment.1
In response to the challenges to pain management raised in the 
literature, better education has been proposed as a solution.1 © The Ulster Medical Society, 2011.
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In addition to health professionals who must be made better 
equipped to assess and therefore manage pain, patients and 
their families must be educated on the proper use of pain 
medications, and concerns regarding their side effects and 
addiction must be addressed.  Only through facilitating open 
communication between professionals who are confident in 
their ability to deal with the complex nature of cancer pain 
and patients who understand and are less intimidated by their 
pain, may the doctor-patient relationship become one in which 
pain is best controlled.
The author has no conflict of interest.
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